GSA Capital Partners LLP Acquires 33,969 Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX)

GSA Capital Partners LLP boosted its holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) by 8.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 435,213 shares of the company’s stock after purchasing an additional 33,969 shares during the quarter. GSA Capital Partners LLP owned approximately 0.59% of Protalix BioTherapeutics worth $444,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new position in shares of Protalix BioTherapeutics during the 2nd quarter valued at approximately $37,000. AQR Capital Management LLC purchased a new stake in Protalix BioTherapeutics in the second quarter worth $67,000. Ground Swell Capital LLC purchased a new position in shares of Protalix BioTherapeutics during the second quarter valued at $73,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Protalix BioTherapeutics during the second quarter valued at $80,000. Finally, Squarepoint Ops LLC increased its stake in shares of Protalix BioTherapeutics by 673.3% during the second quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock valued at $161,000 after buying an additional 119,949 shares during the period. 16.53% of the stock is currently owned by institutional investors.

Protalix BioTherapeutics Stock Performance

Shares of NYSE PLX opened at $1.69 on Thursday. The company has a market cap of $124.44 million, a PE ratio of -13.00 and a beta of 0.67. The business has a 50-day simple moving average of $1.14 and a two-hundred day simple moving average of $1.11. Protalix BioTherapeutics, Inc. has a fifty-two week low of $0.82 and a fifty-two week high of $1.90.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Protalix BioTherapeutics from a “hold” rating to a “buy” rating in a research note on Monday.

Protalix BioTherapeutics Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.